{"schema_version":"1","generated_at":"2026-10-30T18:49:53.940Z","data_as_of":null,"url":"https://www.findmykol.com/kol/lloyd-damon","json_url":"https://www.findmykol.com/kol/lloyd-damon/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"lloyd-damon","name":"Lloyd Damon","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of California, San Francisco","institution_url":"https://www.findmykol.com/institution/university-of-california-san-francisco","city":"San Francisco","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1548224058","orcid":"0000-0002-7934-5321","openalex":"A5061334352"},"summary":"Lloyd Damon is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 179 publications with 8,643 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":179,"cited_by_count":8643,"h_index":36,"latest_activity_year":2024,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00201240","title":"Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","source_url":"https://clinicaltrials.gov/study/NCT00201240","trial_url":"https://www.findmykol.com/trial/NCT00201240"},{"nct":"NCT00020943","title":"Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"Alliance for Clinical Trials in Oncology","source_url":"https://clinicaltrials.gov/study/NCT00020943","trial_url":"https://www.findmykol.com/trial/NCT00020943"}],"source":"trials"},"payments":{"company_count":6,"program_years":{"first":2021,"last":null},"rows_total":6,"shown":3,"withheld":3,"rows":[{"payer":"KAMADA LTD.","program_year":2024,"amount_usd":146.75,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1548224058"},{"payer":"Actelion Pharmaceuticals US, Inc.","program_year":2024,"amount_usd":125.47,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1548224058"},{"payer":"ABBVIE INC.","program_year":2024,"amount_usd":45.26,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1548224058"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1548224058","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.02474","status":"verified"},{"title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","year":2021,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(21)00375-2","status":"verified"},{"title":"Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer","year":2020,"journal":"Molecular Therapy","source_url":"https://doi.org/10.1016/j.ymthe.2020.07.017","status":"verified"},{"title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","year":2019,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(18)30221-7","status":"verified"},{"title":"Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients","year":2019,"journal":"Biology of Blood and Marrow Transplantation","source_url":"https://doi.org/10.1016/j.bbmt.2019.08.022","status":"verified"}],"source":"works"},"contact":{"address_1":"400 PARNASSUS AVE","city":"San Francisco","state":"CA","zip":"941432202","phone":"415-353-2421","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1548224058","source":"identity"},"similar":[{"name":"Adil Daud","slug":"adil-daud","institution":"University of California, San Francisco","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/adil-daud","json_url":"https://www.findmykol.com/kol/adil-daud/profile.json"},{"name":"Emmanuelle Waubant","slug":"emmanuelle-waubant","institution":"University of California, San Francisco","specialty":"Neurology","url":"https://www.findmykol.com/kol/emmanuelle-waubant","json_url":"https://www.findmykol.com/kol/emmanuelle-waubant/profile.json"},{"name":"Peter Ganz","slug":"peter-ganz","institution":"University of California, San Francisco","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/peter-ganz","json_url":"https://www.findmykol.com/kol/peter-ganz/profile.json"},{"name":"Joel Palefsky","slug":"joel-palefsky","institution":"University of California, San Francisco","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/joel-palefsky","json_url":"https://www.findmykol.com/kol/joel-palefsky/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":3,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2008-10-08","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}